RM-MET / Metabolic and incretin signalling
Cotadutide
Also known as: MEDI0382
Grade describes the published research on the molecule. It is not a quality score, a safety score, or a release state.
What this is
Cotadutide is the nonproprietary name for MEDI0382, an investigational dual glucagon/GLP-1 receptor agonist.
Evidence position
Multiple randomized human studies support Grade B, with results across glucose, weight, liver and kidney-related research settings.
What the record does not establish
Those studies do not establish the identity, purity, strength, sterility or stability of any separately labelled material.
Sources
- 01Cotadutide compound recordPubChem
- Shows
- Registry identity, structure, formula and MEDI0382 synonyms
- Does not show
- Chemical identity does not establish clinical status or lot quality
- 02Cotadutide 54-week randomized phase 2b studyPubMed
- Shows
- Human metabolic and hepatic outcomes from a randomized phase 2b study
- Does not show
- Sponsor-involved, protocol-defined evidence; not a market-sample test
- 03Cotadutide phase 2b registry recordClinicalTrials.gov
- Shows
- Official design, intervention and study-status record
- Does not show
- Registration does not establish approval or outside-sample equivalence
External database index
LIVE DATABASE INDEX / SEPARATE FROM CURATED EVIDENCE
Records below come directly from public scientific databases. They help find relevant material, but do not affect the evidence grade until they are matched to the molecule and added to the curated source list.
PUBCHEM / IDENTITY
Cotadutide
- CID
- 134694273
- Formula
- C167H252N42O55
- Mass
- 3728.0
PUBMED / FOUND RECORDS
- Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.Nature metabolism / 2020 MayPMID 32478287 / DOI 10.1038/s42255-020-0209-6
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.Diabetes care / 2021 JunPMID 34016612 / DOI 10.2337/dc20-2151
- GLP-1R/GCGR dual agonism dissipates hepatic steatosis to restore insulin sensitivity and rescue pancreatic β-cell function in obese male mice.Nature communications / 2025 May 21PMID 40399267 / DOI 10.1038/s41467-025-59773-4
- A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease.Kidney international / 2024 DecPMID 39218393 / DOI 10.1016/j.kint.2024.08.023
- Cotadutide promotes glycogenolysis in people with overweight or obesity diagnosed with type 2 diabetes.Nature metabolism / 2023 DecPMID 38066113 / DOI 10.1038/s42255-023-00938-0
CLINICALTRIALS.GOV / FOUND RECORDS
- A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese DescentCOMPLETED / PHASE1 / MedImmune LLCNCT03385369 / DIRECT intervention MATCH: MEDI0382
- A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well ToleratedCOMPLETED / PHASE2 / MedImmune LLCNCT03550378 / DIRECT intervention MATCH: MEDI0382
- A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With FibrosisCOMPLETED / PHASE2 / AstraZenecaNCT05364931 / DIRECT intervention MATCH: Cotadutide
- A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.COMPLETED / PHASE2 / MedImmune LLCNCT04019561 / DIRECT intervention MATCH: Cotadutide
- A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy ParticipantsTERMINATED / PHASE1 / AstraZenecaNCT05668936 / DIRECT intervention MATCH: Cotadutide